Maple Capital Management Inc. Grows Holdings in Edwards Lifesciences Corporation $EW

Maple Capital Management Inc. grew its stake in Edwards Lifesciences Corporation (NYSE:EW) by 7.7% during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 3,852 shares of the medical research company’s stock after purchasing an additional 277 shares during the quarter. Maple Capital Management Inc.’s holdings in Edwards Lifesciences were worth $279,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of EW. Allspring Global Investments Holdings LLC boosted its stake in Edwards Lifesciences by 0.5% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company’s stock valued at $2,170,000 after purchasing an additional 145 shares during the period. Dynamic Advisor Solutions LLC lifted its stake in Edwards Lifesciences by 2.4% during the first quarter. Dynamic Advisor Solutions LLC now owns 15,506 shares of the medical research company’s stock valued at $1,124,000 after purchasing an additional 370 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its stake in Edwards Lifesciences by 13.5% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 77,016 shares of the medical research company’s stock valued at $5,582,000 after purchasing an additional 9,188 shares during the last quarter. United Asset Strategies Inc. raised its holdings in shares of Edwards Lifesciences by 10.4% during the first quarter. United Asset Strategies Inc. now owns 185,571 shares of the medical research company’s stock valued at $13,450,000 after acquiring an additional 17,412 shares during the period. Finally, Farther Finance Advisors LLC raised its holdings in shares of Edwards Lifesciences by 390.7% during the first quarter. Farther Finance Advisors LLC now owns 8,808 shares of the medical research company’s stock valued at $633,000 after acquiring an additional 7,013 shares during the period. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Down 0.4%

Shares of NYSE EW opened at $78.01 on Friday. The firm has a 50 day moving average price of $78.91 and a 200 day moving average price of $75.35. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. Edwards Lifesciences Corporation has a 52-week low of $64.00 and a 52-week high of $83.00. The stock has a market cap of $45.80 billion, a P/E ratio of 11.22, a P/E/G ratio of 3.78 and a beta of 1.07.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The business had revenue of $1.53 billion during the quarter, compared to analysts’ expectations of $1.49 billion. During the same quarter in the prior year, the company posted $0.70 earnings per share. The firm’s revenue was up 11.9% on a year-over-year basis. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Analysts expect that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Insider Transactions at Edwards Lifesciences

In related news, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $78.06, for a total transaction of $698,637.00. Following the sale, the insider directly owned 206,900 shares of the company’s stock, valued at approximately $16,150,614. The trade was a 4.15% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Daniel J. Lippis sold 4,114 shares of the business’s stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $79.46, for a total transaction of $326,898.44. Following the sale, the vice president directly owned 22,002 shares in the company, valued at $1,748,278.92. The trade was a 15.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 22,014 shares of company stock valued at $1,698,844. 1.29% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on EW shares. Mizuho upped their price objective on shares of Edwards Lifesciences from $87.00 to $95.00 and gave the company an “outperform” rating in a research note on Friday, July 25th. Daiwa America raised shares of Edwards Lifesciences from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 29th. JPMorgan Chase & Co. upped their price objective on shares of Edwards Lifesciences from $80.00 to $85.00 and gave the stock a “neutral” rating in a report on Friday, July 25th. Morgan Stanley increased their price target on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the company an “equal weight” rating in a report on Tuesday, July 15th. Finally, William Blair raised shares of Edwards Lifesciences to a “strong-buy” rating in a report on Friday, July 25th. Three investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Edwards Lifesciences currently has an average rating of “Moderate Buy” and a consensus price target of $86.26.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.